Metabolic aspects of the behavior of MPTP and some analogues.
Tipton
K F
KF
Department of Biochemistry, Trinity College, Dublin, Ireland.
McCrodden
J M
JM
Sullivan
J P
JP
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*; D015655:1-Methyl-4-phenylpyridinium / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008995:Monoamine Oxidase / Q000502:physiology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000503:physiopathology; D011726:Pyridinium Compounds / Q000493:pharmacokinetics / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013378:Substantia Nigra / Q000187:drug effects / Q000503:physiopathology
D011726:Pyridinium Compounds; C044755:1-methyl-4-phenyl-2,3-dihydropyridinium; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase; D015655:1-Methyl-4-phenylpyridinium